NCT03675750 is a clinical trial in Schizophrenia, sponsored by Shanghai Mental Health Center.

Who is sponsoring NCT03675750?

NCT03675750 is sponsored by Shanghai Mental Health Center.

What condition does NCT03675750 study?

NCT03675750 studies Schizophrenia.

Is NCT03675750 still recruiting?

NCT03675750 is currently status unknown. Last updated 19 September 2019.

Last reviewed 2019-09-19 · How we verify

NCT03675750

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Hyperprolactinemia Induced by Antipsychotic Drugs on Bone Metabolism

Status unknown Last updated 19 September 2019

What this trial tests

trial in Schizophrenia in 120 participants. Status unknown.

Timeline

1 July 2018

Primary endpoint
30 April 2020

31 October 2020

Quick facts

Lead sponsor	Shanghai Mental Health Center
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	120
Start date	1 July 2018
Primary completion	30 April 2020
Estimated completion	31 October 2020
Sites	1 location across China

Conditions studied

Schizophrenia — all drugs for Schizophrenia →

Sponsor

Shanghai Mental Health Center — full company profile →

Who can join

Adults 18 to 50, any sex, with Schizophrenia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is aimed to assess the severities of hyperprolactinemia caused by antipsychotic drugs and the effects of the duration of hyperprolactinemia on bone metabolism in schizophrenia patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Schizophrenia

Currently open trials in the same condition.

NCT07424404 — A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au · Phase 3 · recruiting
NCT07467993 — Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia · Phase 2 · recruiting
NCT07379827 — Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) · recruiting
NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting

Other Shanghai Mental Health Center trials

Trials by the same sponsor.

NCT07480408 — Neural Mechanisms of the Sensorymotor Circuit in Sensory Phenomena in OCD · NA · not yet recruiting
NCT07479771 — tTIS Targeted of the Striatum as an Intervention for MUD Patients · NA · not yet recruiting
NCT07472673 — Transcranial Temporal Interference Stimulation Targeted of the Amygdala as an Intervention for Alcohol Use Disorder Pati · NA · not yet recruiting
NCT07484750 — Efficacy and Influencing Factors of Mindfulness-Based Exposure Group Therapy for OCD · NA · recruiting
NCT07311655 — Validation of the Accuracy of an AI-Based System for Diagnosing Anxiety Disorders · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03675750 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Mental Health Center
Last refreshed: 19 September 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03675750.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing